BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther 2022;22:1265-74. [PMID: 36408971 DOI: 10.1080/14737140.2022.2150168] [Reference Citation Analysis]
2 Marin JJG, Monte MJ, Macias RIR, Romero MR, Herraez E, Asensio M, Ortiz-rivero S, Cives-losada C, Giacomo SD, Gonzalez-gallego J, Mauriz JL, Efferth T, Briz O. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers. Cancers 2022;14:3524. [DOI: 10.3390/cancers14143524] [Reference Citation Analysis]
3 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022;71:1141-51. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
4 Tan X, Bednarsch J, Rosin M, Appinger S, Liu D, Wiltberger G, Garcia Vallejo J, Lang SA, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, De Vos-Geelen J, Valkenburg-van Iersel L, Clahsen-van Groningen MC, de Jong EJM, Groot Koerkamp B, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann UP, Heij LR. PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2190. [PMID: 35565318 DOI: 10.3390/cancers14092190] [Reference Citation Analysis]
5 Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Front Oncol 2022;12:785535. [DOI: 10.3389/fonc.2022.785535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kim SR, Won HS, Yang JH, Sun S, Yim K, Hong M, Hong SA, Yoon JS, Chun SH, Kim KH, Ko YH. Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. Sci Rep 2022;12:1931. [PMID: 35121803 DOI: 10.1038/s41598-022-05914-4] [Reference Citation Analysis]
8 Cadamuro M, Macias RI, Strain AJ, Strazzabosco M, Simioni P, Marin JJ, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2022;3:5-16. [DOI: 10.1002/lci2.39] [Reference Citation Analysis]
9 Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology 2022;75:297-308. [PMID: 34510503 DOI: 10.1002/hep.32150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
10 Mayr C, Kiesslich T, Modest DP, Stintzing S, Ocker M, Neureiter D. Chemoresistance and resistance to targeted therapies in biliary tract cancer: What have we learned? Expert Opin Investig Drugs 2022. [PMID: 35098846 DOI: 10.1080/13543784.2022.2034785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
12 Tan X, Rosin M, Appinger S, Bednarsch J, Liu D, Wiltberger G, Vallejo JG, Lang S, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, de Vos-geelen J, Iersel LV, Groningen MC, de Jong EJ, Koerkamp BG, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann U, Heij L. PD1+ T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma.. [DOI: 10.1101/2022.01.07.475344] [Reference Citation Analysis]
13 Baria K, De Toni EN, Yu B, Jiang Z, Kabadi SM, Malvezzi M. Worldwide Incidence and Mortality of Biliary Tract Cancer. Gastro Hep Advances 2022;1:618-626. [DOI: 10.1016/j.gastha.2022.04.007] [Reference Citation Analysis]
14 Saborowski A, Vogel A, Segatto O. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends Cancer 2021:S2405-8033(21)00226-0. [PMID: 34840108 DOI: 10.1016/j.trecan.2021.11.001] [Reference Citation Analysis]
15 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
19 Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021;9:CD012814. [PMID: 34515993 DOI: 10.1002/14651858.CD012814.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hack SP, Zhu AX. Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:1007-15. [PMID: 34459336 DOI: 10.1080/13543784.2021.1974838] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer 2021. [PMID: 34309846 DOI: 10.1002/ijc.33751] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Younger NT, Wilson ML, Jarman EJ, Meynert AM, Grimes GR, Gournopanos K, Waddell SH, Tennant PA, Wilson DH, Guest RV, Wigmore SJ, Acosta JC, Kendall TJ, Taylor MS, Sproul D, Mill P, Boulter L. In vivo modelling of patient genetic heterogeneity identifies concurrent Wnt and PI3K activity as a potent driver of invasive cholangiocarcinoma growth.. [DOI: 10.1101/2021.07.05.449722] [Reference Citation Analysis]
23 Roderburg C, Loosen SH, Bednarsch J, Alizai PH, Roeth AA, Schmitz SM, Vucur M, Luedde M, Paffenholz P, Tacke F, Trautwein C, Ulmer TF, Neumann UP, Luedde T. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. Int J Mol Sci 2021;22:6569. [PMID: 34207359 DOI: 10.3390/ijms22126569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Kai Y, Ikezawa K, Takada R, Daiku K, Maeda S, Abe Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Nagata S, Wada H, Ohkawa K. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 2021;5:712-6. [PMID: 34124390 DOI: 10.1002/jgh3.12576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021;74:1021-4. [PMID: 33612309 DOI: 10.1016/j.jhep.2021.01.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Aitcheson G, Mahipal A, John BV. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Expert Opin Investig Drugs 2021;30:463-77. [PMID: 33678096 DOI: 10.1080/13543784.2021.1900821] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
28 Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF. Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer. Onco Targets Ther 2021;14:1873-82. [PMID: 33737812 DOI: 10.2147/OTT.S269671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]